ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
A phase 3 trial of Limertinib, Carboplatin, Cisplatin and Pemetrexed in non-small-cell lung cancer, run by Jiangsu Aosaikang Pharmaceutical Co., Ltd., now recruiting.
Overview
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy is a phase 3 interventional study registered as NCT07109531 by Jiangsu Aosaikang Pharmaceutical Co., Ltd., with 286 participants planned, started 2025-08-04 and due to reach its primary completion in 2027-10-31. Interventions recorded: ASKC202+ Limertinib and Pemetrexed + Cisplatin /Carboplatin.
Similar pages
not linked directly; found by shared links- TrialA Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialCombination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialSavolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.